Logo

American Heart Association

  7
  0


Final ID: LB16

TRANScranial direct current stimulation for POst-stroke motor Recovery - a phase II sTudy (TRANSPORT2) - Main Results

Abstract Body: Stroke remains a leading cause of disability with motor deficit being the most common complication after stroke. Transcranial direct current stimulation (tDCS), a non-invasive brain stimulation technique, has been shown to promote and enhance brain plasticity and to modulate the excitatory and inhibitory interhemispheric imbalance that developed after a stroke. TRANScranial direct current stimulation for POst-stroke motor Recovery - a phase II sTudy (TRANSPORT 2) is the FIRST funded multi-center stroke recovery study on the NIH StrokeNet. The primary aim of this proposal is to determine whether there is an overall treatment effect among the three dosing groups (sham+mCIMT, 2 mA+mCIMT and 4 mA+mCIMT) immediately after 2-week intervention in the Fugl-Myer Upper-Extremity Scale (a measure of motor impairment). Additional outcome measures include the Wolf Motor Function Test Time Score (a measure of functional motor activity), and the Stroke Impact Scale Hand Subscale (a measure of the quality of life). The sustained benefit is assessed at 1 month as well as 3 months post-intervention. Secondary aims will assess safety, tolerability, and feasibility to implement this combined approach in a multi-site trial. An exploratory aim will examine whether weighted corticospinal tract-lesion load (wCST-LL, structural assessment of integrity of descending motor tract) or Motor Evoked Potentials (MEPs, functional assessment of integrity of descending motor tract) or a combination of both are correlated with changes in FM-UE scale, and evaluate the utility of these measures as biomarkers for patient selection criteria in future confirmatory Phase III study. The last patient visit was completed on 10/16/2024 and we expect to lock the final database and unblind the study results on 11/08/2024. 48% of enrolled subjects are non-Caucasians, and the retention of primary endpoint at day 15 is 98%. In addition, there are no safety concern with any group. We are aiming to present the main results at the international stroke conference and publish on the same day if possible.
  • Feng, Wayne  ( Duke University School of Medicine , Chapel Hill , North Carolina , United States )
  • Feld, Jody  ( Duke University , Durham , North Carolina , United States )
  • Schlaug, Gottfried  ( UMass Chan Medical School-Baystate Campus , Springfield , Massachusetts , United States )
  • Cassarly, Christy  ( Medical Univ. of South Carolin , Charleston , South Carolina , United States )
  • Broderick, Joseph  ( University of cincinnati , Cincinnati , Ohio , United States )
  • Wolf, Steven  ( EMORY UNIVERSITY SCHOOL OF MEDICINE , Atlanta , Georgia , United States )
  • Fritz, Stacy  ( , Columbia , South Carolina , United States )
  • Rowe, Veronica  ( Georgia State University , Smyrna , Georgia , United States )
  • Janis, Scott  ( NIH , Bethesda , Maryland , United States )
  • Ramakrishnan, Viswanathan  ( Medical Univ. of South Carolin , Charleston , South Carolina , United States )
  • Charalambous, Charalambos  ( Duke University , Durham , North Carolina , United States )
  • Author Disclosures:
    Wayne Feng: DO have relevant financial relationships ; Consultant:NAMSA:Active (exists now) ; Advisor:Burke rehaibilitation Insitute:Active (exists now) | Jody Feld: DO NOT have relevant financial relationships | Gottfried Schlaug: DO NOT have relevant financial relationships | Christy Cassarly: DO NOT have relevant financial relationships | Joseph Broderick: DO have relevant financial relationships ; Consultant:Roche-Genenetch:Active (exists now) ; Other (please indicate in the box next to the company name):Kroger - Pharmacy Committee:Active (exists now) ; Consultant:Brainsgate:Past (completed) ; Consultant:Basking Bioscience:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) | Steven Wolf: DO NOT have relevant financial relationships | Stacy Fritz: DO NOT have relevant financial relationships | Veronica Rowe: DO NOT have relevant financial relationships | Scott Janis: DO NOT have relevant financial relationships | Viswanathan Ramakrishnan: DO NOT have relevant financial relationships | Charalambos Charalambous: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Thursday Main Event

Thursday, 02/06/2025 , 11:00AM - 12:30PM

ISC Invited Symposium

More abstracts on this topic:
A Trial of Patients Receiving Remote Ischemic Conditioning in Early Stroke (PRICES) in a Tertiary Hospital in the Philippines: An Open Label Study

Ang Kevin Royce, Juangco Dan, Hernandez Maria Kim

A First-in-Class Humanized Antibody Fragment Targeting Platelet Glycoprotein Ibα: A Comprehensive Preclinical Study of CA1001 for the Treatment of Acute Ischemic Stroke

Xu Xiaohong, Preeti Preeti, Yu Ruoying, Shaykhalishahi Hamed, Zhang Cheng, Shen Chuanbin, Li Bei, Tang Naping, Chang Yan, Xiang Qian, Cui Yimin, Lei Xi, Ni Heyu, Zhu Guangheng, Liu Zhenze, Hu Xudong, Slavkovic Sladjana, Neves Miguel, Ma Wenjing, Xie Huifang

More abstracts from these authors:
Panel Discussion and Q&As

Janis Scott, Kleindorfer Dawn

Recombinant Factor VIIa (rFVIIa) for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial

Broderick Joseph, Janis Scott, Steiner Thorsten, Audebert Heinrich, Bath Philip, Molina Carlos, Dowlatshahi Dar, Toyoda Kazunori, Grotta James, Naidech Andrew, Elm Jordan, Khatrip Pooja, Vagal Achala, Wang Lily, Aviv Richard, Mayer Stephan

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)